Issay Kitabayashi
Overview
Explore the profile of Issay Kitabayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2853
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hattori A, Takamatsu-Ichihara E, Yamamoto Y, Fujita S, Yamagata K, Katsumoto T, et al.
Leukemia
. 2023 Jul;
37(9):1812-1829.
PMID: 37491463
The chromatin-associated AAA+ ATPases Tip48 and Tip49 are the core components of various complexes implicated in diverse nuclear events such as DNA repair and gene regulation. Although they are frequently...
2.
Ito J, Yamagata K, Shinohara H, Shima Y, Katsumoto T, Aikawa Y, et al.
Int J Hematol
. 2022 Oct;
117(1):78-89.
PMID: 36280659
Disease-risk stratification and development of intensified chemotherapy protocols have substantially improved the outcome of acute lymphoblastic leukemia (ALL). However, outcomes of relapsed or refractory cases remain poor. Previous studies have...
3.
Shinohara H, Sawado R, Nakagawa M, Hattori A, Yamagata K, Tauchi K, et al.
Mol Ther Oncolytics
. 2022 Oct;
27:14-25.
PMID: 36212776
Malignant rhabdoid tumors (MRTs) are rare and highly aggressive pediatric cancers with no standard of care. MRTs are characterized by loss of SMARCB1, which results in upregulated expression of enhancer...
4.
Katsumoto T, Ogawara Y, Yamagata K, Aikawa Y, Goitsuka R, Nakamura T, et al.
Blood Adv
. 2022 Aug;
6(19):5527-5537.
PMID: 35947126
Monocytic leukemia zinc finger protein (MOZ, MYST3, or KAT6A) is a MYST-type acetyltransferase involved in chromosomal translocation in acute myelogenous leukemia (AML) and myelodysplastic syndrome. MOZ is established as essential...
5.
Nakagawa M, Yamaguchi M, Endo M, Machida Y, Hattori A, Tanzawa F, et al.
J Bone Oncol
. 2022 May;
34:100430.
PMID: 35493690
Background: Chondrosarcoma is a common form of malignant bone tumor with limited treatment options. Approximately half of chondrosarcomas harbor gain-of-function mutations in isocitrate dehydrogenase (IDH), and mutant IDH produces 2-hydroxyglutarate...
6.
Takeuchi Y, Kimura N, Murayama T, Machida Y, Iejima D, Nishimura T, et al.
Proc Natl Acad Sci U S A
. 2021 Oct;
118(43).
PMID: 34663724
Although it is held that proinflammatory changes precede the onset of breast cancer, the underlying mechanisms remain obscure. Here, we demonstrate that FRS2β, an adaptor protein expressed in a small...
7.
Nakagawa M, Sekimizu M, Endo M, Kobayashi E, Iwata S, Fukushima S, et al.
J Orthop Sci
. 2021 Sep;
27(6):1315-1322.
PMID: 34531086
Background: Mutant isocitrate dehydrogenase (IDH) in chondrosarcoma produces the oncometabolite 2-hydroxyglutarate (2-HG) and contributes to malignant progression, and is therefore a potential therapeutic target for chondrosarcoma. Robust historical control data...
8.
Kishimoto K, Kanazawa K, Nomura M, Tanaka T, Shigemoto-Kuroda T, Fukui K, et al.
Cancer Med
. 2021 Jun;
10(13):4451-4464.
PMID: 34145991
Background: Effective treatments for cancer harboring mutant RAS are lacking. In Drosophila, it was reported that PP6 suppresses tumorigenicity of mutant RAS. However, the information how PP6 regulates oncogenic RAS...
9.
Yamagata K, Shino M, Aikawa Y, Fujita S, Kitabayashi I
Leukemia
. 2021 May;
35(10):2840-2853.
PMID: 33967269
Chromosome translocations involving the MLL gene are common rearrangements in leukemia. Such translocations fuse the MLL 5'-region to partner genes in frame, producing MLL-fusions that cause MLL-related leukemia. MLL-fusions activate...
10.
Kagiyama Y, Fujita S, Shima Y, Yamagata K, Katsumoto T, Nakagawa M, et al.
Cancer Sci
. 2021 Apr;
112(6):2314-2324.
PMID: 33792119
Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin's lymphoma, which is characterized by overexpression of cyclin D1. Although novel drugs, such as ibrutinib, show promising clinical outcomes, relapsed...